Achilles Therapeutics

Achilles Therapeutics plc operates as a clinical-stage biopharmaceutical company headquartered in London, United Kingdom. Founded in May 2016 by a team of world-class scientists—Professor Charles Swanton, Professor Karl Peggs, Dr. Sergio Quezada, and Professor Mark Lowdell—the company was established to leverage groundbreaking research from University College London (UCL), the Francis Crick Institute, and Cancer Research UK. The founders' collective expertise in cancer evolution, bioinformatics, and immunotherapy laid the foundation for the company's core mission. The initial science originated from the TRACERx study, a significant investment by Cancer Research UK to track the evolution of non-small cell lung cancer in detail.

The company's central focus is on developing personalized T-cell therapies designed to target clonal neoantigens, which are unique protein markers present on the surface of every cancer cell in an individual patient but absent from healthy tissues. This approach aims to create highly specific treatments that can destroy tumors without causing harm to healthy cells. To achieve this, Achilles utilizes its proprietary PELEUS™ bioinformatics platform, an AI-powered tool that analyzes patient-specific DNA sequencing data to identify these clonal neoantigens. The business model revolves around the research, development, and eventual commercialization of these precision therapies for patients with solid tumors. As a clinical-stage company, its revenue generation is not yet based on product sales but on investment and partnerships.

Achilles went public with an Initial Public Offering (IPO) on the Nasdaq in March 2021, raising approximately $175.5 million. This milestone provided the capital to advance its clinical programs. The company has had two main Phase I/IIa clinical trials: the CHIRON trial for patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial for those with recurrent or metastatic melanoma. However, in September 2024, Achilles announced a significant strategic shift, discontinuing the development of its tumor-infiltrating lymphocyte (TIL)-based therapy after the trials did not meet goals for commercial viability. This led to the closure of the CHIRON and THETIS trials and a refocusing of the company's strategy. The new direction involves exploring partnerships with third parties to use its clonal neoantigen targeting technology in other modalities like vaccines and antibody-drug conjugates (ADCs). Subsequently, in December 2024, Achilles announced the sale of key technology assets, including data from the TRACERx study and its Material Acquisition Platform, to AstraZeneca for $12 million.

Keywords: T-cell therapies, clonal neoantigens, immuno-oncology, personalized medicine, cancer evolution, bioinformatics platform, solid tumors, clinical trials, biopharmaceutical, cancer vaccines